Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016

  • ID: 4030240
  • Drug Pipelines
  • 52 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Genzyme Corp
  • Pharnext SA
  • MORE
Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016, provides an overview of the Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline landscape.

Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. Symptoms include distal weakness and atrophy, sensory loss, foot deformities, and slow nerve conduction velocity. The disorder is caused by a duplication of the PMP22 gene on Chromosome 17. Symptomatic treatment includes pain medication, physical therapy and surgery.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Charcot-Marie-Tooth Disease Type I A - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type I A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Charcot-Marie-Tooth Disease Type I A (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Genzyme Corp
  • Pharnext SA
  • MORE
Introduction

Charcot-Marie-Tooth Disease Type I A Overview

Therapeutics Development

Pipeline Products for Charcot-Marie-Tooth Disease Type I A - Overview

Pipeline Products for Charcot-Marie-Tooth Disease Type I A - Comparative Analysis

Charcot-Marie-Tooth Disease Type I A - Therapeutics under Development by Companies

Charcot-Marie-Tooth Disease Type I A - Therapeutics under Investigation by Universities/Institutes

Charcot-Marie-Tooth Disease Type I A - Pipeline Products Glance

Late Stage Products

Early Stage Products

Charcot-Marie-Tooth Disease Type I A - Products under Development by Companies

Charcot-Marie-Tooth Disease Type I A - Products under Investigation by Universities/Institutes

Charcot-Marie-Tooth Disease Type I A - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Affectis Pharmaceuticals AG

Genzyme Corp

Lead Discovery Center GmbH

Pharnext SA

Charcot-Marie-Tooth Disease Type I A - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(baclofen + naltrexone hydrochloride + sorbitol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AFC-5128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Charcot-Marie-Tooth Disease Type I A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Charcot-Marie-Tooth Disease Type 1A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Charcot-Marie-Tooth Disease Type I A - Dormant Projects

Charcot-Marie-Tooth Disease Type I A - Product Development Milestones

Featured News & Press Releases

Dec 20, 2016: Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Nov 17, 2016: Pharnext Announces that the Data Safety Monitoring Board Recommends Continuing the Ongoing Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

Oct 04, 2016: Pharnext Announces Support of the First Patient-Centered Charcot-Marie-Tooth Summit Organized by the Hereditary Neuropathy Foundation

Sep 01, 2016: Pharnext’s PXT3003 Featured in Multiple Presentations at the 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (CMTR) Meeting

Apr 25, 2016: Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A

Feb 16, 2016: Pharnext Supports the Fight Against Rare Diseases through Development of Pleotherapy-based Treatments

Dec 15, 2015: Pharnext Initiates PLEO-CMT, an International Pivotal Phase 3 Trial, in Charcot-Marie-Tooth disease type 1A

Jun 30, 2015: Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting

Dec 17, 2014: Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A through Two Peer-Reviewed Publications

Oct 21, 2014: Addex And The Charcot-Marie-Tooth Association Enter Collaboration To Advance ADX71441 In Charcot-Marie-Tooth 1A disorder

Jun 23, 2014: The EMA and FDA Grant Orphan Drug Designation to Pharnext's PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A

Apr 24, 2013: Addex Receives Approval To Initiate Phase I First-In-man Clinical Study For ADX71441

Jan 22, 2013: Addex Receives Broad US Composition Of Matter Patent For ADX71441

Jan 07, 2013: Addex Therapeutics Announces Positive Data With ADX71441 In Pre-Clinical Transgenic Model Of Charcot-Marie-Tooth 1A Disease

Nov 22, 2011: Pharnext Completes Patient Recruitment For Phase II Study Of PXT3003 In Type 1A Charcot-Marie-Tooth Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Charcot-Marie-Tooth Disease Type I A, H2 2016

Number of Products under Development for Charcot-Marie-Tooth Disease Type I A - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Charcot-Marie-Tooth Disease Type I A - Pipeline by Addex Therapeutics Ltd, H2 2016

Charcot-Marie-Tooth Disease Type I A - Pipeline by Affectis Pharmaceuticals AG, H2 2016

Charcot-Marie-Tooth Disease Type I A - Pipeline by Genzyme Corp, H2 2016

Charcot-Marie-Tooth Disease Type I A - Pipeline by Lead Discovery Center GmbH, H2 2016

Charcot-Marie-Tooth Disease Type I A - Pipeline by Pharnext SA, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Charcot-Marie-Tooth Disease Type I A - Dormant Projects, H2 2016

List of Figures:

Number of Products under Development for Charcot-Marie-Tooth Disease Type I A, H2 2016

Number of Products under Development for Charcot-Marie-Tooth Disease Type I A - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • Affectis Pharmaceuticals AG
  • Genzyme Corp
  • Lead Discovery Center GmbH
  • Pharnext SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll